This independent medical education activity features an expert interview with Giuseppe Saglio, MD, and Juan Luis Steegmann, MD, PhD, focusing on observations from an important publication reporting on the 24-month follow-up of the phase III randomized ENESTnd trial comparing nilotinib and imatinib for the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). (Kantarjian HM, et al. Lancet Oncol. 2011;12(9):841-851)

This independent medical education activity features an expert interview with Elias Jabbour, MD, and Jane Apperley, MD, focusing on important data from a recent publication assessing the correlation of an early complete cytogenetic response (CCyR) and survival in patient with early chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors.